Exploring the Relationship Between Glial Cells and Electromagnetic Waves David Dardashti and Quantum Electrodynamic Ibogaine By David Dardashti supports quantum...
DURHAM, NC / ACCESSWIRE / March 14, 2024 / The Glioblastoma Foundation is proud to be a charity partner for...
STOCKHOLM, SWEDEN / ACCESSWIRE / March 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
ATLANTA, GA / ACCESSWIRE / March 13, 2024 / A leading advocate in the fight against ALS, Hop On A...
Study Demonstrates That Patients Achieved Long-Term Visual Acuity Gains Following CureSight TreatmentAIRPORT CITY, ISRAEL / ACCESSWIRE / March 13, 2024...
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system...
Event hosted by the U.S. Army Medical Research and Development Command’s (USAMRDC) Combat Casualty Care Research Program (CCCRP) Neurotrauma Portfolio...
Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8® for the treatment of ALS with the objective of submitting...
Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary data from ADVANCED-2...
PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE...
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug...
LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...
VAN NUYS, Calif.--(BUSINESS WIRE)--The Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System...
The Princess Royal was introduced to the first FDA-cleared portable MR brain imaging system being used to test the disparities...
-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month ---- Study will evaluate the use...
Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for...
TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
The Canadian startup has gained exclusive access to the U.S. accelerator, including funding, resources, and engagement with world-renowned health organizationsTORONTO--(BUSINESS...
TORONTO, ON / ACCESSWIRE / March 11, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
– STRIDE Phase 2 primary endpoint of PASI 75 and key secondary endpoints met at all clinically relevant doses tested;...